BIRC5 and renal fibrosis: These findings are of great clinical translational potential because pharmacological inhibitors of TP53RK (fusidic acid, FA, an FDA‐approved bacteriostatic antibiotic)[11] and Birc5 (YM‐155, an anticancer agent in phase 2 clinical trials)[12] have been well developed and both can attenuate renal fibrosis in unilateral ureteral obstruction (UUO) mice.